9.81
+0.39(+4.14%)
Currency In USD
Address
1100 Winter Street
Waltham, MA 02451
United States of America
Phone
617 433 2605
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6
First IPO Date
July 30, 2020
| Name | Title | Pay | Year Born |
| Mr. Vikas Sinha C.A., CPA, M.B.A. | Chief Executive Officer, President, Chief Financial Officer & Director | 544,400 | 1963 |
| Mr. David L. Hallal | Executive Chairman of the Board | 200,000 | 1966 |
| Mr. Edward Miller J.D. | General Counsel & Secretary | 645,693 | 1965 |
| Mr. Brett R. Hagen | Chief Accounting Officer | 796,311 | 1973 |
| Dr. Ann M. Leen Ph.D. | Chief Scientific Officer | 0 | 1977 |
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.